Inventor · disambiguated record
Kenneth J. Mandell
Also filed as: MANDELL KENNETH · MANDELL KENNETH J · MANDELL KENNETH JASON
20 granted patents·9 pending applications·188 citations·filing 2011–2024
96Inventor score
Files withOYSTER POINT PHARMA INC14ALDEYRA THERAPEUTICS INC9LAYERBIO INC3NOVEOME BIOTHERAPEUTICS INC2MANDELL KENNETH J1
Top patents by PatentIndex Score
29 records- 0198US11007157B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2020·Granted May 18, 2021·15 cites·41 claims
- 0297US11771664B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2022·Granted Oct 3, 2023·4 cites·16 claims
- 0397US11701331B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2021·Granted Jul 18, 2023·7 cites·41 claims
- 0496US11911380B2Compositions and use of varenicline for treating dry eyeOYSTER POINT PHARMA INC·Filed 2023·Granted Feb 27, 2024·2 cites·30 claims
- 0596US11903941B2Compositions and use of varenicline for treating dry eyeOYSTER POINT PHARMA INC·Filed 2021·Granted Feb 20, 2024·2 cites·24 claims
- 0696US11903943B2Compositions and use of varenicline for treating dry eyeOYSTER POINT PHARMA INC·Filed 2023·Granted Feb 20, 2024·2 cites·30 claims
- 0796US11224598B2Methods of increasing lacrimal proteinsOYSTER POINT PHARMA INC·Filed 2019·Granted Jan 18, 2022·6 cites·19 claims
- 0896US10588874B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2019·Granted Mar 17, 2020·20 cites·41 claims
- 0996US10543181B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2019·Granted Jan 28, 2020·17 cites·30 claims
- 1096US10213395B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2017·Granted Feb 26, 2019·24 cites·40 claims
- 1195US11903942B2Compositions and use of varenicline for treating dry eyeOYSTER POINT PHARMA INC·Filed 2023·Granted Feb 20, 2024·1 cites·30 claims
- 1295US9687481B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2014·Granted Jun 27, 2017·28 cites·35 claims
- 1395US2025127733A1Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1494US10456396B2Dry eye treatmentsOYSTER POINT PHARMA INC·Filed 2017·Granted Oct 29, 2019·9 cites·100 claims
- 1594US9597284B2Dry eye treatmentsOYSTER POINT PHARMA INC·Filed 2015·Granted Mar 21, 2017·11 cites·15 claims
- 1694US9532944B2Methods of improving ocular discomfortOYSTER POINT PHARMA INC·Filed 2015·Granted Jan 3, 2017·12 cites·15 claims
- 1794US9504644B2Methods of increasing tear productionOYSTER POINT PHARMA INC·Filed 2015·Granted Nov 29, 2016·11 cites·15 claims
- 1894US9504645B2Pharmaceutical formulations for treating ocular conditionsOYSTER POINT PHARMA INC·Filed 2015·Granted Nov 29, 2016·10 cites·13 claims
- 1992US12128013B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·0 cites·20 claims
- 2090US10709707B2Methods of treating ocular conditionsOYSTER POINT PHARMA INC·Filed 2017·Granted Jul 14, 2020·7 cites·72 claims
- 2190US2024173318A1Dry eye treatmentsOYSTER POINT PHARMA INC·Filed 2024·Application pending·0 cites
- 2282US2025000861A1Methods of treating ocular conditionsOYSTER POINT PHARMA INC·Filed 2024·Application pending·0 cites
- 2366US2023042169A1Ocular device delivery methods and systemsLAYERBIO INC·Filed 2022·Application pending·0 cites
- 2463US11185441B2Ocular device delivery methods and systemsLAYERBIO INC·Filed 2020·Granted Nov 30, 2021·0 cites·30 claims
- 2562US2020345734A1Methods of treating ocular conditionsOYSTER POINT PHARMA INC·Filed 2020·Application pending·0 cites
- 2658US2020147145A1Methods for Reducing the Extent of Light-induced Tissue Inflammation and InjuryNOVEOME BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2755US2018271914A1Methods for Reducing the Extent of Light-induced Tissue Inflammation and InjuryNOVEOME BIOTHERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2836US2013273137A1Drug delivery coating and devicesMANDELL KENNETH J·Filed 2011·Application pending·0 cites
- 2920US2017028078A1Sustained-release drug formulations for glaucomaLAYERBIO INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kenneth J. Mandell files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →